Spero Therapeutics, Inc.
SPRO Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$1.11
KIRA · Stoqly’s AI analyst, in plain words
- Spero Therapeutics, Inc. had $66.8M of revenue in fiscal 2025, up 39.2% on the year before. Over five years, revenue changed +48.2% a year on average.
- Its operating margin was 9.5%, up 162.4 pts: of every 100 in sales, about 9 is left after running the business.
- Spero Therapeutics, Inc. made $8.6M of net profit in fiscal 2025.
Market cap
$64.3M
P/E
7.9x
Revenue
$66.8M
Net income
$8.6M
Free cash flow
—
Operating margin
9.5%
Spero Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+39.2%
Yes. Sales grew 39.2% last year.
Does it make a profit?
12.8%
Yes. It keeps 12.8% of every sale as profit.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
How is the share priced?
7.9x
One share costs 7.9 times its yearly profit per share.
What Spero Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Legal name
- Spero Therapeutics, Inc.
- CIK
- 0001701108
Spero Therapeutics, Inc. · SPRO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $18.3M | $53.5M | $104M | $48.0M | $66.8M |
| Revenue growth | 95.7% | 193.1% | 94.0% | −53.8% | 39.2% |
| Operating margin | −481.9% | −78.9% | 20.7% | −152.9% | 9.5% |
| Net income | −$89.8M | −$46.4M | $22.8M | −$68.6M | $8.6M |
| Net margin | −491.9% | −86.7% | 22.0% | −142.9% | 12.8% |
| Diluted EPS | −$2.91 | −$1.23 | $0.43 | −$1.27 | $0.15 |
| Cash | |||||
| Cash from operations | −$64.3M | −$7.7M | −$33.0M | −$23.4M | −$12.6M |
| Share count change | 38.0% | 21.7% | 41.0% | 2.0% | 9.3% |
| Debt and strength | |||||
| Cash and short-term investments | $146M | $109M | $76.3M | $52.9M | $40.3M |
| Shareholders' equity | $88.3M | $75.9M | $107M | $46.1M | $59.0M |
| Current ratio | 8.5x | 5.2x | 3.5x | 2.2x | 7.6x |
| Returns and quality | |||||
| Return on equity | −81.5% | −56.5% | 24.9% | −89.6% | 16.3% |
| Return on tangible equity | −101.7% | 61.1% | 21.3% | −148.7% | 14.5% |
| Piotroski F-score | 2 | 3 | 3 | 1 | 4 |
| Altman Z'' | −4.0 | −6.6 | −1.3 | −13.8 | −8.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.6M
2 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Spero Therapeutics, Inc. · SPRO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.11 a share, the company is worth $64.3M: 7.9 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001701108). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.